Taiho
mokuji

Portfolio · The Register

Twenty-three positions, ten years.

The list below is the public face of the cap-table register. Active and exited positions in oncology, immunology, and platform biology. The order is alphabetical, not chronological — a venture portfolio is a syndicate of years, not a ranking.

  1. 01Anavo Therapeutics
  2. 02Arcus BiosciencesOncology
  3. 03Breakpoint TherapeuticsOncology
  4. 04cellviePlatform
  5. 05Cullinan OncologyOncology
  6. 06Delphia Therapeutics
  7. 07Dren Bio
  8. 08EpiBiologicsPlatform
  9. 09Halda TherapeuticsOncology
  10. 10Harpoon TherapeuticsOncology
  11. 11Incendia Therapeutics
  12. 12LiberoTheraImmunology
  13. 13Light Horse TherapeuticsPlatform
  14. 14Magnet BiomedicinePlatform
  15. 15NextCureOncology
  16. 16NormunityOncology
  17. 17ORIC PharmaceuticalsOncology
  18. 18Orna TherapeuticsPlatform
  19. 19STORM TherapeuticsPlatform
  20. 20TheolyticsOncology
  21. 21Transition BioPlatform
  22. 22Vertero
  23. 23Werewolf TherapeuticsOncology

On the same wires

Most of these rounds were led by someone else. The recurring names in the syndicate columns are the ones you would expect for early-stage oncology in this decade: ARCH, GV, MPM, Pfizer Ventures, RA Capital, Bessemer, OrbiMed. Taiho is rarely the first wire and almost never the largest. The seat we take is the one a $400M Japanese specialty pharmaceutical company is permitted to take — a syndicate position, taken seriously.

Contact

On a round of your own?

If you are running a syndicate that fits the filter — oncology first, Series A–B by default — write the partners. We read every note.

partners@taihoventures.comBegin an outreach →